Hansoh Pharma Stock Draws HKD 47.73 Target From 24 Analysts
Published on 10/20/2026 at 19:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and valuation
- Simply Wall St listed a HKD 47.73 consensus target from 24 analysts on October 17, 2026.
- Hansoh Pharma reported CNY 8.30 billion in first-half 2026 revenue, up 11.70 percent year over year.
- Hansoh Pharma stock costs EUR 3.89 at Lang & Schwarz on October 20, 2026 at 7:39 p.m. CEST.
- The company had HKD 208.4 billion in market capitalization and a 26.83 price-to-earnings ratio on October 20, 2026.
Hansoh Pharma stock has a HKD 47.73 average 12-month analyst target from 24 analysts, according to Simply Wall St on October 17, 2026. Against the HKD 31.74 share price used in that consensus table, the target is 50.41 percent above the price. Hansoh Pharma was trading at EUR 3.89 at Lang & Schwarz on October 20, 2026 at 7:39 p.m. CEST.
Revenue growth meets high margins
The latest reported period points to a profitable growth profile. In the first half of 2026, Hansoh Pharma generated CNY 8.30 billion in revenue, up 11.70 percent from the first half of 2025, while profit reached CNY 4.26 billion, up 35.80 percent year over year, according to VCBeat. Innovative-drug revenue totaled CNY 7.09 billion, or 85.40 percent of total revenue, and increased 21.60 percent year over year.
Stock range and trading picture
On the Hong Kong Stock Exchange, the stock last traded at HKD 34.38 on October 20, 2026 at 4:08 p.m. HKT, with the market closed. The 52-week range was HKD 28.06 to HKD 44.22, while volume reached 35,387,819 shares on the session.
The current market capitalization was HKD 208.4 billion on October 20, 2026. Its price-to-earnings ratio was 26.83, compared with a 16.60 peer average in the valuation table, while the company itself was listed at 24.60 times earnings.
Dates and valuation matter
The company had reported its first-half 2026 results on August 26, 2026. The next valuation question is whether innovative medicines can maintain their 85.40 percent revenue share while the pipeline expands beyond oncology.
Stock position for investors
Hansoh Pharma combines a large innovative-drug contribution with a 26.83 price-to-earnings ratio and a market capitalization of HKD 208.4 billion. The analyst target provides a separate benchmark, but it is denominated in HKD and should not be compared directly with the EUR quote.
Current trading level
The EUR quote from Lang & Schwarz places the stock at EUR 3.89 on October 20, 2026 at 7:39 p.m. CEST. The Hong Kong listing closed at HKD 34.38 on the same date at 4:08 p.m. HKT.
The further course of trading is shown by the continuously updated real-time quote of Hansoh Pharma stock.
Hansoh Pharma stock at a glance
- Company: Hansoh Pharmaceutical Group Company Limited
- ISIN: KYG549581067
- Ticker: 3692.HK
- Primary exchange: Hong Kong Stock Exchange
- Price Lang & Schwarz (as of October 20, 2026, 7:39 p.m. CEST): EUR 3.89
- Market capitalization: HKD 208.4 billion (as of October 20, 2026)
- 52-week range: HKD 28.06-HKD 44.22 (as of October 20, 2026)
- Sector / Industry: Healthcare / specialty and generic drug manufacturers
Market context: Current market reports.
